impact view overal found result rel neutral
revenu guidanc quarter modestli lower midpoint
due fx organ c/c growth reiter adj ebitda adj ep
guidanc rais mid-point high end prior
guidanc respect addit adj ebitda adj ep beat mse
quarter respect reflect oper leverag
busi transport growth slow organ c/c slowest quarter
sinc due recal digit market soft segment
consist strong perform past four year subscript growth
within transport remain strong non-subscript
deceler flat resourc outperform expect grow
third straight quarter cautiou sustain strength
resourc given declin energi industri capital-expenditure project
rystad model vs correl
data resources/energi growth rate past year ipreo
return double-digit growth august y/i expect
abl hit origin annual revenu guidanc
guidanc pull remain uw stock trade -turn
analyt peer ex standard ev/ebitda despit lower
top-lin growth ntm organ vs peer rais dcf-base pt
follow model updat primari driver
marking-to-market current debt yield ep rise
driven mainli quarter beat adj ep declin
primarili due higher share count
capit alloc updat seek board approv octob initi
dividend believ posit attract broader investor base
highlight cash flow stabil target gross leverag
typic oper high end rang target annual capit return
sharehold minimum annual capac
would includ potenti dividend yield remaind made
share repurchas invest
recap miss mse top-lin beat adj ebitda adj ep
due margin expans financi servic post
compani trade less week
unless otherwis note metric base modelwar
base consensu methodolog
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
strong quarter grow organ subscript organ growth
non-subscript organ growth downstream price opu
chemic contribut strong quarter transport organ growth
subscript organ growth non-
subscript organ growth impact slowdown digit
advertis financi servic organ growth driven double-digit
growth price index deriv process return growth
quarter grew organ quarter benefit boiler code
revenu adj ebitda margin beat mse adj ep beat
mse
deriv discount cash ow valuat wacc risk-fre rate
market risk premium beta termin growth rate base case
lead supplier
vertic attract busi model
believ current elev valuat
standard ev/ebitda
growth
segment reliant
upstream energi capital-expenditure volatil
depend crude price
dcf-base pt impli downsid
view descript risk reward theme
organ revenu growth
compound-annual-growth-rate adj ebitda margin
encompass higher growth rate
oper margin base case full
credit target revenu cost
synergi
organ revenu growth
compound-annual-growth-rate adj ebitda margin
growth lacklust
energi environ continu
moder margin benet scale
acquisit synergi credit half
revenu full cost synergi
organ revenu growth
compound-annual-growth-rate adj ebitda margin
industri vertic especi
lower oper margin
base case credit revenu cost
margin expansiondriven cost synergi scale
platform initi
price wallet share product develop
china india
view explan region hierarchi
research highest favor quintil
acquisit prove dilutive/low growth
expect
includ hedg fund asset held mspb result
could contradict may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
exhibit quarterli revenu segment
exhibit statement flow
